Sevelamer Hydrochloride Tablet, Film Coated
Product Images NDC 55154-2647

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Hydrochloride (NDC 55154-2647). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

800mg Bag Label (C13532a7 4c56 4084 839d 3dcfd4dc30f8 00)

800mg Bag Label (C13532a7 4c56 4084 839d 3dcfd4dc30f8 00)
Label of sevelamer hydrochloride tablets, film coated, 800 mg strength, in a package containing 10 tablets. The label includes dosage form and quantity, barcode, storage instructions, and distributor information listing Cardinal Health 107, LLC. The label also notes this unit dose is not child resistant and is intended for institutional use only.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of sevelamer hydrochloride, showing its polymeric molecular arrangement with repeating units containing amine groups bound to hydrochloride and hydroxy-functionalized side chains.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph comparing the percentage of patients with at least a certain reduction in serum phosphorus levels (mg/dL) for sevelamer hydrochloride and an active control. The x-axis shows the reduction in serum phosphorus from baseline, ranging from -4 to 8 mg/dL, while the y-axis shows the percentage of patients, ranging from 0 to 100%. The graph indicates changes classified as worsened increase and improved reduction.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph showing phosphorus change from baseline over 52 study weeks. Two treatment groups are compared: Sevelamer Hydrochloride and Active Control. Phosphorus levels decrease from baseline initially, with Sevelamer Hydrochloride maintaining slightly greater reduction throughout the study period.*
FDA Label Image
Glenmark-logo (Glenmark Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.